TOMA announces the release of its COMPASSTM Tumor Profiling System – a simple efficient way to analyze tumor DNA. The system includes a simple complete workflow from preparing the tumor DNA library for sequencing and then performing comprehensive somatic focused data analysis. In addition, TOMA has established partnerships to provide clinical annotation and report generation. With the release of COMPASS, clinical research laboratories have everything they need to identify somatic variants within tumor DNA.
During this 45-minute session, TOMA scientists will:
- Introduce the COMPASSTM Tumor Profiling System
- Provide key results and findings from our recent method paper
- Discuss how COMPASSTM is working through regulatory requirements for FDA approval and has developed protocols for CLIA/CAP and MolDx validation required for successful reimbursement